Kurakin G F, Lopina N P, Bordina G E
Tver State Medical University, Ministry of Health of the Russian Federation, Tver, 170000 Russia.
Mol Biol (Mosk). 2020 Mar-Apr;54(2):341-352. doi: 10.31857/S002689842002010X.
The leukotriene B4 receptors BLT1 and BLT2 are promising targets for the treatment of allergic and inflammatory diseases. However, no working model of ligand binding to either of these receptors has been developed so far. Under the assumption that homologous receptors bind their ligands in a similar way, computational modeling of agonist binding to BLT1 and BLT2 was performed using fully flexible docking in Galaxy 7TM. For both receptors, the carboxyl group of the ligand forms a salt bridge with an arginine residue, while the tail hydroxyl groups form hydrogen bonds with three amino acid residues. The differential specificity of ligands to BLT1 and BLT2 is explained by the replacement of histidine with tyrosine. In BLT1, the histidine residue binds the 5-OH group of the ligand, while the tyrosine residue in BLT2 repels it. The presented models are in agreement with experimental data and may be useful for developing new BLT1- and BLT2-targeted drugs.
白三烯B4受体BLT1和BLT2是治疗过敏性和炎性疾病的有前景的靶点。然而,迄今为止尚未建立这两种受体中任何一种与配体结合的有效模型。在同源受体以相似方式结合其配体的假设下,使用Galaxy 7TM中的完全柔性对接对激动剂与BLT1和BLT2的结合进行了计算建模。对于这两种受体,配体的羧基与一个精氨酸残基形成盐桥,而尾部羟基与三个氨基酸残基形成氢键。配体对BLT1和BLT2的差异特异性可通过组氨酸被酪氨酸取代来解释。在BLT1中,组氨酸残基结合配体的5-OH基团,而BLT2中的酪氨酸残基则排斥它。所提出的模型与实验数据一致,可能有助于开发新的靶向BLT1和BLT2的药物。